Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NVAX with free AI briefings, catalyst countdowns, and dilution alerts.

NVAX · NOVAVAX INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$622.4M Cash on Hand
22.4mo Cash Runway
Follow NVAX by email Get an email when NVAX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NVAX, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Novavax COVID-19 Vaccine COVID-19 Phase 4 · NCT06065176 Completed
Pfizer COVID-19 mRNA vaccine (2023-2024 formula… COVID-19 Phase 4 · NCT06065176 Completed
Pfizer mRNA COVID-19 vaccine COVID-19 Phase 4 · NCT06633835 Completed
protein subunit: Novavax COVID-19 vaccine COVID-19 Phase 4 · NCT06633835 Completed
Aluminum Hydroxide Adjuvanted Inactivated… Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Phase 3 · NCT05249816 Completed
Bivalent BA.4/5 COVID-19 Phase 2/3 · NCT05925127 Completed
CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS… COVID-19 Phase 3 · NCT06291857 Completed
coformulated CIC Vaccine COVID-19 Phase 2/3 · NCT06482359 Withdrawn
Fluzone HD trivalent COVID-19 Phase 2/3 · NCT06482359 Withdrawn
Trivalent Influenza Vaccine COVID-19 Phase 3 · NCT06291857 Completed
Quadrivalent Inactivated Influenza Vaccine Influenza, Human Phase 3 · NCT04120194 Completed
Formulation buffer Respiratory Syncytial Virus Infections Phase 3 · NCT02624947 Completed
Licensed seasonal influenza vaccine SARS-CoV-2 Infection Phase 3 · NCT04583995 Completed
NanoFlu Influenza, Human Phase 3 · NCT04120194 Completed
SARS-CoV-2 rS Nanoparticle Vaccine NVX-CoV2373 COVID-19 Phase 3 · NCT05463068 Completed
NVX-CoV2515 COVID-19 Phase 3 · NCT05372588 Completed

Also used in these trials (approved or third-party drugs, not NVAX's own candidates): Saponin-based Adjuvant, Adjuvant, SARS-CoV-2 rS antigen/Matrix-M Adjuvant, Dose 1 of Aluminum Adjuvant, Dose 2 of Aluminum Adjuvant, Dose 3 of Aluminum Adjuvant, Dose 4 of Aluminum Adjuvant, Adjuvant 1, Matrix-M Adjuvant, Monovalent Avian Influenza VLP (H5N1); Adjuvant.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NVAX holds $622.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $83.5M/quarter from operations, an estimated runway of 22.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 8 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NVAX files for a raise →

👥 Who Owns NVAX

Insiders 0.6% Other 5%+ holders 6.5% Institutions (348 holders) 67.8% Public and other holders 25.1%
HolderTypeShares% of sharesAs of
Himanshu H. Shah 5%+ holder (13D) 10,656,964 6.46% 2026-10-16
STATE STREET CORPORATION Institution (13G, 5%+) 8,827,707 5.35% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 8,305,681 5.03% 2026-03-31
John C Jacobs
President and CEO, Director · +1.77M options
Insider 225,680 0.14% 2026-03-03
Elaine O'Hara
EVP, Chief Strategy Officer · +625,666 options
Insider 134,642 0.08% 2026-03-03
James Patrick Kelly
EVP, CFO and Treasurer · +662,499 options
Insider 130,599 0.08% 2026-03-07
Mark J Casey
EVP, Chief Legal Officer · +454,899 options
Insider 90,067 0.05% 2026-03-03
David M Mott
Director · +49,596 options
Insider 79,770 0.05% 2026-06-18
Richard Douglas
Director · +49,596 options
Insider 73,220 0.04% 2026-06-18
Gregg H Alton
Director · +49,596 options
Insider 47,685 0.03% 2026-06-18
Richard J Rodgers
Director · +49,596 options
Insider 47,370 0.03% 2026-06-18
Margaret G Mcglynn
Director · +49,596 options
Insider 44,468 0.03% 2026-06-18

Share count 165,009,009 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NVAX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NVAX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.